PMID-29514064 – NAD-Boosting Molecules In Vivo Evidence
Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metabolism. 2018;27(3):529-547.
Quick Reference
| Property | Value |
|---|---|
| PMID | 29514064 |
| DOI | 10.1016/j.cmet.2018.02.011 |
| Year | 2018 |
| Journal | Cell Metabolism |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | N/A (review) |
| Peptide(s) Studied | NAD+ |
Key Findings
- Comprehensive review of in vivo evidence for NAD-boosting molecules including NMN, NR, nicotinamide (NAM), and nicotinic acid (NA)
- Covers therapeutic applications across metabolic disease, neurodegeneration, cardiovascular disease, cancer, and aging in animal models
- Published in Cell Metabolism (impact factor ~29), establishing the Sinclair lab's framework for translating NAD+ precursor research toward clinical use
Study Design
Narrative review from David Sinclair's laboratory at Harvard Medical School. Systematically catalogues published in vivo studies of NAD+ precursor molecules across multiple disease models, organized by therapeutic area. Evaluates pharmacokinetics, tissue-specific NAD+ elevation, and dose-response relationships across preclinical models.
Limitations
- Predominantly based on preclinical animal data; limited human trial data available at time of writing
- Potential conflict of interest as senior author (Sinclair) holds patents and equity in NAD+-related companies
Clinical Relevance
Serves as the definitive in vivo evidence base for NAD+ precursor supplementation, guiding clinical trial design and informing practitioners about the breadth of potential therapeutic applications for NAD+ boosting strategies.
Related
#research #narrative-review #evidence-level-V